Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Phase I Clinical Trial to Evaluate Dimethylfumarate (DMF) in Relapsed/Refractory Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Sponsor: Michael Choi
Terminated
lack of funding
Other Chronic Lymphocytic Leukemia trials with similar outcome
This PHASE1 trial investigates Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma and is currently terminated or withdrawn. Michael Choi leads this study, which shows 11 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Oct 2019 — Jan 2021 [monthly]
Terminated PHASE1
-
Apr 2019 — Oct 2019 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
▶ Show 6 earlier versions
-
Feb 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE1
-
Jan 2019 — Feb 2019 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jun 2018 — Jan 2019 [monthly]
Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — May 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Michael Choi
- The Leukemia and Lymphoma Society
For direct contact, visit the study record on ClinicalTrials.gov .